Skip to main content

Table 4 Rare diseases significantly enriched in hypermethylated DMCs in the LGA group according to Enrichr [36]

From: Methylation analysis by targeted bisulfite sequencing in large for gestational age (LGA) newborns: the LARGAN cohort

Term

Overlap

P value

Adjusted P value

Odds ratio

Combined score

Genes

Branchial arch defects

17/142

1.83E-06

0.004

4.372

57.765

GCM2;TFAP2A;TBX1;FOXC1;TWIST2;GATA3;KY;TBX2;SHH;CYP26B1;CXCL12;SIX2;HAND2;PAX9;MSX1;PITX1;NKX2-3

Ulnar-mammary syndrome

11/63

3.11E-06

0.004

6.759

85.712

TFAP2A;TBX1;FGF17;TBX15;CDKN1A;SHH;BMP2;MYC;TBX5;JUNB;TBX2

Dominant cleft palate

23/267

9.61E-06

0.009

3.042

35.149

TFAP2A;TBX1;CDKN1A;KCNK9;WNK4;TWIST2;HOXC13;KLF4;KY;CKAP4;SKI;SHH;BMP2;TERT;PTER;ESRP2;MYC;PAX9;KRT14;DVL1;COL9A3;MSX1;PITX1

Renal agenesis bilateral

11/77

2.29E-05

0.016

5.321

56.867

CDKN1A;PTER;PAX8;WT1;SIX2;LHX1;GATA3;NOTUM;AQP2;ACTB;MNX1

Malignant cylindroma

22/282

6.75E-05

0.032

2.724

26.160

FOXA1;CDKN1A;FOXC1;DYSF;GATA3;KLK8;KLK10;CKAP4;PURA;GJA1;CXCL12;TERT;PAX8;WT1;ALPP;MYC;ERBB2;CD9;COL9A3;PGR;CSK;ADA

Mayer-Rokitansky-Kuster-Hauser syndrome

12/103

7.78E-05

0.032

4.212

39.852

NR5A1;IL32;MUC1;SRD5A2;PTER;WT1;LHX1;WNT9B;PGR;AMH;TBX5;KY

Urethral cancer

12/103

7.78E-05

0.032

4.212

39.852

SHH;TERT;PAX8;ALPP;WT1;MYC;ERBB2;GATA3;AMH;KY;CKAP4;ADRA2A

Symphalangism distal

11/94

1.47E-04

0.035

4.228

37.300

SHH;HBM;BMP2;PTER;MYC;PRRX2;SP6;HOXC13;MSX1;GDF5;CKAP4

Glassy cell carcinoma of the cervix

4/10

1.61E-04

0.035

21.108

184.317

MUC1;ERBB2;KY;CKAP4

Split hand foot malformation

14/146

1.72E-04

0.035

3.391

29.406

WNT10A;AMN;LBX1;CKAP4;GJA1;SHH;PTER;MYC;LHX1;HAND2;PAX9;SP6;MSX1;ADA

Testicular cancer

12/115

2.25E-04

0.035

3.719

31.244

TFAP2A;CDKN1A;TERT;SRD5A2;PAX8;ALPP;WT1;MYC;ERBB2;CD9;AMH;KY

22q11.2 deletion syndrome

12/116

2.44E-04

0.035

3.683

30.642

GCM2;SLC25A1;TBX1;SHH;CYP26B1;PTER;HAND2;GATA3;PRODH;TBX5;MED15;TBX2

Gordon syndrome

15/171

2.73E-04

0.035

3.076

25.246

TBX1;IL11;OSR1;WNK4;STK39;AQP5;OXSR1;KY;SHH;PTER;PAX8;MYC;SCNN1B;WNK2;APOE

Leydig cells hypoplasia

15/171

2.73E-04

0.035

3.076

25.246

UCN;CDKN1A;EGR3;SRD5A2;OSR1;HSPA2;NR5A1;GJA1;BMP2;SHH;WT1;SIX2;ERBB2;PTGDS;AMH

Meleda disease

11/101

2.80E-04

0.035

3.897

31.891

UCN;GJA1;WNT10A;JUP;MYC;KRT14;AQP5;EVPL;KY;KRT6A;KRT9

Palmoplantar keratoderma

11/101

2.80E-04

0.035

3.897

31.891

UCN;GJA1;WNT10A;JUP;MYC;KRT14;AQP5;EVPL;KY;KRT6A;KRT9

Cleft lip and/or palate with mucous cysts of lower

12/118

2.86E-04

0.035

3.613

29.483

TFAP2A;TBX1;BMP2;SHH;TERT;PTER;BHMT2;PAX9;WNT9B;MSX1;KY;CKAP4

Cleft lip palate-tetraphocomelia

12/118

2.86E-04

0.035

3.613

29.483

TFAP2A;TBX1;BMP2;SHH;TERT;PTER;BHMT2;PAX9;WNT9B;MSX1;KY;CKAP4

Aortic arches defect

5/20

2.88E-04

0.035

10.566

86.152

TBX1;BMP2;HAND2;FOXH1;GATA3

Talipes equinovarus

21/292

3.01E-04

0.035

2.489

20.180

CDKN1A;OSR1;WNK4;STK39;HOXC13;HOXC12;HOXD11;GDF5;HOXD10;CELSR3;KY;TBX2;COL1A1;SKI;PURA;TERT;PTER;CYP1B1;HYLS1;MSX1;PITX1

  1. Only pathways with corrected p < 0.05 are shown